Content hub
The 17th edition of the Evaluate World Preview is here and this is the place to find everything you need to know.
Featuring pharma forecasts out to 2030, we investigate the drivers of an exciting 7.7% growth rate and ask whether the recent uncertainties in the market have gone away (spoiler alert – they haven’t).
More World Preview 2024 Content
If you’re not familiar with the piece, it’s a deep dive into the state of the biopharma market, using Evaluate’s pharma forecasts to uncover key trends, challenges and drivers of growth (or indeed headwinds) for the coming years.
If you missed the session, you’ll be pleased to know it’s available on demand. Meanwhile, here are three key takeaways from the discussion to whet your appetite.
Access our world-class forecasting, analysis and machine learning-driven insight to help you reduce risk, maximise returns, and make smarter decisions about your portfolio strategy.
Dive into our market reports covering sector performance and valuation, emerging trends and global forecasts. Stay ahead of the competition with the latest developments that impact your portfolio strategy.
Tap into our expertise and reach your goals with our collaborative team of specialists, providing technology-enabled consulting, strategic commercial insights, and recommendations across the product lifecycle.
Evaluate gives you the understanding and time you need to drive better decisions.
Identify the market that offers the greatest potential for your business so you can confidently prioritise assets and allocate resources.
Develop a robust view of potential partners and licensing opportunities to boost your pipeline and amplify your commercial success.
Build a clear analysis of the evolving landscape – market dynamics, emerging trends and key players – and make strategic moves that strengthen your position.
Monitor key companies so you can track potential partners and competitors and find opportunities in a constantly changing environment.
Obtain a clear and unbiased assessment of asset value to drive licensing decisions and ensure you invest in assets with the highest potential for success.
Bring confidence to your allocation strategy with timely external benchmarking data across the R&D landscape.
November 4-6, 2024 | Stockholm
Why not book a meeting if you would like to hear how Evaluate can help support your strategic decision-making?
